In contrast, African-derived prostate tumours showed a diminished frequency for TMPRSS2–ERG, which is common for European patients, and ESCC tumours showed a decreased frequency for TP53 mutations, although it remained the top candidate driver. Here, TP53 is linked to neoplasm.